South Dakota 2023 Regular Session

South Dakota House Bill HB1236

Introduced
2/1/23  

Caption

Regulate tetrahydrocannabinol for medical use.

Impact

If enacted, HB 1236 would have significant implications for state laws regulating medical cannabis and industrial hemp. It introduces detailed provisions on how cannabis establishments should operate, including guidelines for manufacturing, labeling, and testing cannabis products. By emphasizing adherence to safety standards, the bill aims to protect public health and ensure that patients receive safe products. Moreover, it establishes procedures for the registration of medical cannabis establishments and nonresident cardholders, which would streamline the regulatory process and potentially increase access to cannabis for patients with qualifying conditions.

Summary

House Bill 1236 seeks to regulate tetrahydrocannabinol (THC) specifically for medical use, addressing various aspects of the medical cannabis framework in South Dakota. The bill proposes amendments to existing laws governing industrial hemp, particularly focusing on the cultivation, processing, and distribution of cannabis products. This legislation outlines comprehensive requirements for medical cannabis establishments, including safety standards for the production and sale of cannabis, ensuring that products are manufactured, labeled, and tested in compliance with established regulations. The intent is to create a structured and safe environment for cannabis use within medical contexts while maintaining control over its production and distribution.

Contention

While there is support for the structured regulation of medical cannabis, concerns may arise regarding the bill's provisions, particularly around isomerization of cannabinoids. Stakeholders might debate the appropriateness of restrictions on how cannabis products can be created and marketed. Some may argue that such regulations could inhibit innovation in the cannabis industry, while others may emphasize the necessity of stringent oversight to protect consumers. The legislative discussion is expected to highlight these points of contention, balancing the need for regulation with the entrepreneurial opportunities in the cannabis market.

Companion Bills

No companion bills found.

Similar Bills

NJ S2313

Prohibits sale of tetrahydrocannabinol products in certain circumstances.

NJ A3580

Prohibits sale of tetrahydrocannabinol products in certain circumstances.

MD HB12

Cannabis - Sale and Distribution - Tetrahydrocannabinol Offenses

MD SB214

Cannabis - Sale and Distribution - Tetrahydrocannabinol Offenses

AZ SB1453

Hemp-derived impairing cannabinoids; regulation

CA AB1256

Employment discrimination: cannabis screening test.

HI SB1633

Relating To Hemp.

LA SB143

Enacts Alison Neustrom Act and provides relative to prescribed marijuana for therapeutic uses and the development of rules and regulations by the Louisiana Board of Pharmacy and the Louisiana State Board of Medical Examiners. (gov sig)